• Greater Twin Cities: 715.294.4371

GraftWorx Wins Preclinical In-Kind Services from Surpass as Part of the Rosenman Institute’s 2015 Innovation Award

August 31, 2015

Emerging Medical Device Company, GraftWorx, Wins Preclinical In-Kind Services from Surpass as Part of the Rosenman Institute’s 2015 Innovation Award.

Preclinical Services through Rosenman Innovation Award.jpg

OSCEOLA, WI and MOUNTAIN VIEW, CA (PRNewswire-iReach) — Surpass, Inc. (“Surpass”), a recognized leader in preclinical research services for the medical device industry, announced today that GraftWorx won in-kind services from Surpass as part of the recent Rosenman Institute’s Innovation Awards. The Rosenman Institute, an initiative of California life science accelerator QB3, accelerates the development of medical devices by pairing early-stage medical device entrepreneurs with experienced medical device professionals and valuable resources. The goal of the Rosenman Innovation Awards is to propel those promising ideas towards commercialization.

“The Surpass team is committed to being present, visible and involved in the biomedical communities where we do business. By offering Surpass’ preclinical in-kind services as part of this award, we help drive medical innovation companies beyond early-stage financing challenges. The preclinical proof-of-concept data generated de-risk the opportunity for potential investors and ultimately help advance these life-improving products into the hands of physicians and patients,” says Surpass CEO, Tim Pelura, PhD. “Not only does Surpass provide the research services through the entire study process but we also assist entrepreneurs during due diligence to better the chances of moving their technologies forward into the clinic. By supporting programs like QB3 and the Rosenman Institute Innovation Awards, together we can advance value-driven innovation and ensure the health of the medical innovation continuum.”

GraftWorx is turning the Internet of Things into the Internet of the Body by enabling current vascular prostheses such as stents and bypass grafts to become “smart.” They build smart prosthetics and then leverage their cloud-based algorithms to improve patient’s lives. Their first product is expected to save 40,000 amputations in the US each year, a cost savings of hundreds of millions of dollars. “We are grateful to receive preclinical services as part of the Rosenman Institute’s Innovation Award,” said David Kuraguntla, GraftWorx Founder and CEO. “The data generated from this award will complete the package necessary to obtain later stage financing for our ”smart-prosthetic” technology and ultimately support our product launch into the clinic.”

About Surpass

At Surpass, our innovative approach to preclinical research goes beyond the ordinary. We’re changing the rules for a better way to get from concept to reality.

Surpass is a trusted, preclinical contract research organization with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our preclinical testing services in large in vivo models and human cadavers span the product development cycle (proof-of-concept, early feasibility, iterative prototype evaluations, human factors assessments, validation, pharmacokinetics (PK), GLP/safety studies, and physician/clinical bio-skills training).

At Surpass, we bring more to our client partners. Our award-winning Research Team provides insightful solutions and assistance every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful.

Connect with Surpass, Inc. on, LinkedIn, YouTube, TwitterFacebook, and Google+